UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 5, 2012 |
Amarillo Biosciences, Inc. |
| (Exact Name of registrant as specified in its charter) |
| |
Texas0-20791 75-1974352 | 0-20791 | 75-1974352 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| |
4134 Business Park Drive, Amarillo, Texas 79110-4225 |
(Address of principal executive offices) (Zip Code) |
| |
Registrant’s telephone number, including area code (806) 376-1741 |
| |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 (a) | Departure of Officer |
Dr. Joseph M Cummins retired as President and COO of the Company effective November 30, 2012. As of December 1, 2012 he will begin working for the Company as a consultant.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | AMARILLO BIOSCIENCES, INC. |
Date: December 5, 2012 | By: /s/ Stephen T. Chen |
| | Stephen T. Chen, Chairman of the Board, and Chief Executive Officer |
